Overview of Экофурил

Property	Description
Active ingredient	Nifuroxazide (INN)
Forms	Oral Capsules, Oral Suspension (Liquid)
Pharmacological Class	Intestinal Anti-infective, Nitrofuran Derivative
Common Use	Management of acute bacterial disturbances in the gut
Origin	Synthetic Compound

1. What is the Active Component and Classification of Ecofuril?

The core therapeutic component in Ecofuril is the active substance Nifuroxazide (INN), a synthetic antibacterial compound. This chemical entity is classified by the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system under the code A07AX03, placing it in the high-level pharmacological category of an intestinal anti-infective. As a Nitrofuran derivative, Nifuroxazide functions specifically as an antibacterial agent, utilizing a chemical structure (C12H9N3O5) developed to interfere with the vital systems of susceptible bacteria. Nifuroxazide is clinically recognized for its ability to address gastrointestinal issues stemming from specific bacterial overgrowth.

2. Is Ecofuril a Systemic Antibiotic, and What is its Primary Purpose?

Ecofuril is designed as a non-systemic agent, meaning the Nifuroxazide is engineered to be poorly absorbed into the patient’s bloodstream after oral administration. This is a critical distinction, as its intended localized effect is confined primarily to the intestinal lumen. The primary purpose of the medication is to exert this focused antibacterial action directly at the site of infection. This targeted activity aims to suppress the growth and proliferation of pathogenic microorganisms, providing general relief in situations like acute infectious diarrhea.

3. What Pharmaceutical Forms is Nifuroxazide Available in?

The active compound Nifuroxazide is provided in two main dosage forms for oral use: solid capsules and a liquid oral suspension. Both products are single-ingredient formulations, containing the defined amount of Nifuroxazide alongside standard pharmaceutical excipients. The oral suspension form is specifically positioned for use in pediatric populations and ensures flexibility in administration compared to solely offering capsules, providing the non-systemic anti-infective agent in both formats.

What side effects are possible with Экофурил?

Possible side effects and safety information

The safety profile of Nifuroxazide (the active ingredient in Экофурил) is documented through regulatory channels, detailing potential adverse reactions and necessary restrictions for use.

Documented Adverse Reactions

The most significant safety concerns are related to hypersensitivity, with reactions officially grouped by System-Organ Classes (SOCs) as follows:

Immune system disorders: These include general hypersensitivity reactions, which are the main focus of serious adverse reaction warnings.
Skin and subcutaneous tissue disorders: Documented reactions include rash, pruritus (itching), and urticaria (hives), which are categorized as uncommon or rare in official reports.
Gastrointestinal disorders: Transient gastrointestinal discomfort, nausea, and vomiting have been reported.

Serious adverse reactions are primarily linked to severe allergic responses. The regulatory safety data classifies events such as anaphylactic shock and angioedema (swelling of the face, tongue, or larynx) as very rare or having a not known frequency, reflecting reliance on spontaneous post-marketing reports.

Safety Considerations for Specific Populations

Nifuroxazide carries specific contraindications and cautions based on clinical data and non-clinical findings:

Infants: The medicine is contraindicated in infants under 3 months of age and often in children under 2 years in some jurisdictions due to insufficient safety data in this population.
Pregnancy and Mutagenic Potential: Use during pregnancy is generally advised against as a precaution. This is based on regulatory notes concerning in vitro and in vivo findings that indicate possible mutagenic potential.
Drug Interactions: Caution is advised when Nifuroxazide is used concurrently with highly plasma protein-bound drugs with narrow therapeutic indices (e.g., Warfarin). This warning stems from the potential for competition at binding sites, which could affect the action of the co-administered drug.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding overdose for Экофурил (nifuroxazide) is limited. The prescribing information states that specific symptoms of overdose are not known and are therefore not documented in the product labeling.

In the event of an overdose, no specific procedures or clinical manifestations are detailed in the official government documents. The required emergency action is restricted to symptomatic treatment. There is no mention of substances, dose levels, or circumstances that increase the risk of overdose, nor are there any population- or condition-specific overdose notes provided in the official text.

Since nifuroxazide is minimally absorbed from the gastrointestinal tract, systemic toxicity is not expected to be a major concern at standard doses. However, in the absence of a defined overdose presentation, patients are advised to consult a healthcare professional immediately if they suspect they have taken more than the recommended amount or experience any unexpected severe symptoms. The official regulatory documents do not provide a high-level severity classification for an overdose. The focus remains on supportive care for any symptoms that may arise.

Therapeutic Uses of Экофурил

What Экофурил Treats: Main Uses and Benefits

Экофурил (Ekofuril) is an intestinal anti-infective medicine whose active ingredient is nifuroxazide, a nitrofuran derivative. The main therapeutic domain for this medication is the management of acute, presumed, or confirmed bacterial diarrhea, and the drug is categorized as an intestinal anti-infective.

Core Therapeutic Application

This medicine is considered relevant for easing symptoms that interfere with daily functioning and is applied in addressing conditions involving inflammatory or irritative processes. It is commonly used in clinical scenarios that involve acute or unstable symptom patterns, specifically when patients experience acute episodes of diarrhea of infectious origin, gastroenteritis, or enterocolitis.

The medicine is relevant when supportive symptom management is appropriate, offering symptomatic relief that helps patients cope more steadily during phases when symptoms become more noticeable. This support assists with maintaining functional stability during periods where symptoms become temporarily overwhelming, thus contributing to easing the overall symptom load.

“Offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Symptoms related to physical discomfort.

Eligibility and Restrictions for Use

The eligibility for using Экофурил (Nifuroxazide) is strictly defined by regulatory documents, setting clear restrictions based on age, underlying conditions, and physiological status.

Formal Contraindications (Must Not Use)

Contraindicated Group	Restriction Basis
Hypersensitivity	Known allergy to Nifuroxazide, other drug components, or nitrofuran derivatives.
Infants (Suspension)	New-borns and premature infants (0–1 month) are formally excluded.
Children (Capsules)	The capsule dosage form is contraindicated for children under 15 years of age in some territories.
Metabolic Disorders	Patients with fructose intolerance, glucose-galactose malabsorption, or sucrase/isomaltase deficiency due to excipients.

Eligibility by Population Status

Age Rules: The oral suspension form is officially indicated for use in children from 1 month of age. Adults and adolescents are eligible for the capsule form.
Pregnancy: Use should be avoided as a precaution due to a lack of sufficient human clinical data.
Lactation: Use during breastfeeding is possible but is generally limited to short-term treatment.
Organ Impairment: The drug label advises that caution is necessary when administering to patients with pre-existing hepatic (liver) or renal (kidney) impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction documentation for Nifuroxazide focuses on constraints with specific substance categories, as the drug is partially absorbed and metabolized systemically. This profile is structured around two key regulatory classifications.

Category	Official Regulatory Constraint
Contraindicated Combination	Alcohol (Ethanol)
Clinically Significant Interaction	Oral Anticoagulants

Substances Requiring Formal Prohibition

Co-administration with alcohol (Ethanol) is formally prohibited according to regulatory labeling. This is classified as a contraindicated combination due to the risk of a severe intolerance reaction, often described as disulfiram-like, stemming from the drug's potential to interfere with the metabolism of alcohol. This restriction applies to all alcohol-containing products and is a mandatory constraint for patients undergoing Nifuroxazide treatment.

Interactions Requiring Close Monitoring

Nifuroxazide has a documented interaction with oral anticoagulants, such as Warfarin. Official regulatory information states that this combination carries a risk of pharmacodynamic enhancement of the anticoagulant's effect. The resulting increase in bleeding risk necessitates close procedural monitoring of coagulation parameters, such as the International Normalized Ratio (INR), to manage the officially recognized exposure risk of the co-administered anticoagulant. No mandatory timing or separation rules are explicitly documented for this drug.

Mechanism of Action

Экофурил's mechanism of action involves two main complementary pathways to influence intestinal physiology, focusing primarily on localized activity within the gut lumen.

Localized Antimicrobial Action

This domain centers on the active ingredient, nifuroxazide, a nitrofuran derivative. It directly targets key biochemical pathways in susceptible bacteria by blocking dehydrogenase activity and inhibiting the respiratory chain and the tricarboxylic acid (Krebs) cycle. This molecular interference disrupts essential microbial biochemical processes, resulting in the disruption of the integrity of the bacterial cell membrane and a reduction in the biosynthesis of specific microbial toxins. This action influences signaling cascades that modulate bacterial-mediated dysregulation within the intestinal environment.

Selective Gut Microbiome Modulation

This mechanistic domain is addressed by the combination of nifuroxazide and the prebiotic component, lactitol. Nifuroxazide is notable for demonstrating minimal inhibitory concentration against components of the beneficial intestinal microflora. Lactitol simultaneously acts as a nutrient substrate for the proliferation of select beneficial intestinal microbiota. The combination influences the biological competition between targeted microorganisms and the commensal microbiota, affecting the relative concentrations of luminal mediators.

Dosage and Administration Information

How to Use Экофурил

The administration of the intestinal anti-infective nifuroxazide (the active component of Экофурил) is governed by specific instructions established in official product labeling. The medication is restricted to the oral route of administration, utilizing dosage forms such as capsules (commonly 200 mg) and oral suspension.

Dosing and Frequency

The standard dosing regimen for acute administration is a total daily dose of 800 mg for adults and adolescents. This quantity is typically administered in divided doses, most commonly as 200 mg taken four times daily. Treatment is explicitly intended for short-term use, and the duration is strictly limited, often not to exceed three to seven days.

Administration and Preparation

Capsules should be swallowed with water. When administering the liquid dosage form, the oral suspension must be shaken well immediately before measuring and taking the dose to ensure the active ingredient is uniformly distributed. This preparation step is essential for proper administration of the liquid formulation.

Population Constraints

Official instructions regarding use in younger patients vary significantly by region. While some labels permit use in children over a certain age, restrictions have been imposed in some markets on use in pediatric patients, formally designating the medicine as contraindicated in children and adolescents under 18 years. This constraint defines the population for which the medicine is officially intended in those regions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Экофурил

Evidence for Use in Acute Diarrhea and Intestinal Infections

Research exploring Nifuroxazide, the active ingredient in Экофурил, was studied for its use in patients with acute diarrheal syndrome. The core research includes multiple short-term Randomized Controlled Trials (RCTs) and meta-analyses that have examined this medicine. These trials were applied in research contexts involving fluctuating or unstable symptoms and were designed to provide insight into outcomes related to physical discomfort.

Studies explored what outcomes reflecting daily functioning or activity level were measured during the periods of heightened symptom activity. The research measured intervals such as the time to the last unformed stool, as well as monitoring the frequency and consistency of bowel movements. Studies report how symptoms evolved in the observed populations when Nifuroxazide was compared to a control or placebo group.

Comparing Nifuroxazide to Placebo and Other Treatments

Clinical trials have studied Nifuroxazide by comparing it against an inactive substance (placebo) or against other specific agents used for acute intestinal issues. This comparative research explored the measured outcomes related to physical discomfort in these groups over defined time intervals. Studies monitored how symptoms, such as abdominal pain, evolved to provide context on patient-reported outcomes describing perceived discomfort. The trials aimed to contextualize these findings when Nifuroxazide was evaluated in a comparative setting.

Evidence in Special Populations

Research examined the use of Nifuroxazide across different age groups, including adults and children with acute diarrheal episodes. These studies was evaluated in populations facing conditions involving periods of heightened symptoms. This evidence helps show what was evaluated in these two key groups. Specific research has also been conducted for groups such as travelers experiencing diarrhea.

Long-Term Studies and Follow-up Durations

Research focusing on the acute phase of diarrhea typically involves follow-up periods that are brief. The majority of core studies was observed in research exploring short-term symptom changes over defined time intervals, typically 3 to 7 days. Because of this focus on the acute phase, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of response or the recurrence of symptoms.

What is Still Uncertain About Nifuroxazide Research

While research has contributed to the broader evidence landscape, several areas of uncertainty remain. Some foundational placebo-controlled data were generated in older studies, and the evidence quality varies across studies. Furthermore, its role is not universally incorporated into all major international infectious disease guidelines. Data for certain groups remain insufficient, and subgroup findings are uncertain for several populations, including individuals with certain comorbidities. The results apply only to the populations studied and research does not determine whether an individual can predict their personal outcome.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Экофурил (FAQ)

Q: Are there specific food types that should be avoided while taking Экофурил?

Regulatory documents emphasize the constraint concerning alcohol. Co-administration with alcohol (ethanol) is formally prohibited due to the risk of a severe intolerance reaction often described as disulfiram-like. Official product labeling does not document specific constraints regarding non-alcoholic food types.

Q: Can people with lactose intolerance use Экофурил?

Official product labeling advises that this medicine may be contraindicated (should not be used) if a patient has specific inherited metabolic disorders such as fructose intolerance or glucose-galactose malabsorption. This is due to the presence of certain non-active ingredients (excipients). Patients with known intolerance or allergy to excipients, including lactose, should consult a healthcare professional regarding the full formulation.

Q: What happens if I miss a dose of Экофурил?

Official patient information typically advises that if a dose is missed, it can be taken as soon as it is remembered. However, if the time for the next dose is near, the missed dose is usually skipped to prevent a double dose.

Q: Why do some official sources recommend taking Экофурил with food?

The official product information generally states that the medication can be taken with or without food. However, some regulatory summaries note that taking it along with food may help minimize the risk of transient gastrointestinal discomfort.

Q: What is the risk of developing resistance when using Экофурил?

As with any anti-infective medication, the potential for bacteria to develop resistance is a documented risk. Specific details regarding the product's microbiological profile and resistance susceptibility are found in the official product documentation.

Q: Are there documented cases of overdose with Экофурил?

The official product information includes a section detailing overdose management. Symptoms listed in the event of an overdose may include severe gastrointestinal effects such as nausea, vomiting, and stomach pain.

Q: Does the package insert for Экофурил describe any delayed side effects?

Regulatory summaries of evidence largely focuses on short-term symptom changes over defined intervals, typically 3 to 7 days. Because of this limited follow-up, regulatory summaries state that long-term effects are not fully established, and there is limited official information regarding delayed outcomes.

Q: Is the active substance in Экофурил studied for uses beyond digestive issues?

According to official regulatory labeling, the active substance is indicated for the management of acute bacterial disturbances in the gut (such as acute diarrheal syndrome). No other uses are formally approved or listed in the core indications.

Q: Does Экофурил interact with common painkillers like ibuprofen?

Regulatory documents advise caution when taking nifuroxazide with drugs that are highly plasma protein-bound, as this could affect how those other medications work. While this warning covers drugs like anticoagulants (blood thinners), official regulatory summaries do not explicitly list a specific interaction warning for common over-the-counter painkillers such as ibuprofen.

Q: Is it common to experience nausea when taking Экофурил?

Transient gastrointestinal discomfort, including nausea and vomiting, are reported adverse reactions associated with this medicine. While official reports categorize some side effects (such as rash) as uncommon or rare, the specific frequency or commonality of nausea is not consistently classified in the available regulatory summaries.

Q: Are there different strengths of Экофурил available?

The capsule dosage form is most commonly available in a 200 mg strength for acute treatment. The medicine is also provided as a liquid oral suspension. The full range of available strengths for both formulations is typically found on the specific local product label.

Q: Can Экофурил cause changes in stool color or consistency?

Clinical studies for this medication focus on and monitor changes in the frequency and consistency of bowel movements as they are primary measures of effect. However, official regulatory documentation does not specifically describe changes in stool color as a documented adverse reaction.

Q: What are the known components of the excipients (non-active ingredients) in the drug?

Official product labeling indirectly points to the presence of specific excipients, such as those related to fructose and glucose metabolism, by listing contraindications for associated metabolic disorders. The full, detailed list of all non-active components is published within the official product documentation (such as the SmPC or patient leaflet).

Q: Are there specific official guidelines on who should monitor their blood sugar while using Экофурил?

Official contraindications include patients with glucose-galactose malabsorption due to excipient content. A general requirement for all patients to monitor their blood sugar is not universally stated in the regulatory labeling, but patients with pre-existing metabolic conditions may need to exercise caution.

Q: Are there any specific concerns for elderly patients taking Экофурил?

Official labeling suggests that no specific dose adjustment is needed solely based on advanced age. Regulatory summaries note that caution is typically warranted for elderly patients due to the higher likelihood of pre-existing age-related issues, such as hepatic (liver) or renal (kidney) impairment, which may influence the product's use.

Q: Are there restrictions on driving or operating machinery while using Экофурил?

There are no specific restrictions for driving or operating machinery formally listed in the regulatory documents. However, official documentation advises patients to be aware of potential documented side effects, such as dizziness, which could affect the ability to safely perform these activities.

How should Экофурил be stored and disposed of?

Official Storage and Disposal Requirements

Scope Element	Regulatory Requirement
Storage Temperature	Store at a temperature not exceeding 25 C (for capsules) or 30 C (general).
Protection	Must be stored in a dry place and protected from light.
Handling/Container	Keep in the original container; Do not freeze (especially suspension).
Child Safety	Keep out of the sight and reach of children.
Stability After Opening	Oral suspension must be discarded within 28 days of first opening.
Disposal	Dispose of unused or expired medicine according to local regulations.

The regulatory labeling requires Экофурил to be kept at controlled room temperature and protected from moisture, light, and freezing. The product must be stored in its original packaging and inaccessible to children. Disposal of the unused medicine must follow proper pharmaceutical waste procedures, such as drug take-back programs, or household disposal by mixing with an undesirable substance.

Экофурил